Discontinued — last reported Q2 '25
Thermo Fisher Scientific Redeemable NCI decreased by 5.4% to $122.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.7%, from $120.00M to $122.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates a potential future cash outflow obligation, which could impact liquidity.
This represents equity interests in subsidiaries held by third parties that have redemption features, allowing the holde...
Common in companies with complex joint ventures or partially owned subsidiaries.
redeemable_noncontrolling_interests| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $122.00M | $113.00M | $117.00M | $119.00M | $116.00M | $123.00M | $113.00M | $118.00M | $118.00M | $119.00M | $115.00M | $127.00M | $120.00M | $128.00M | $126.00M | $129.00M | $122.00M |
| QoQ Change | — | -7.4% | +3.5% | +1.7% | -2.5% | +6.0% | -8.1% | +4.4% | +0.0% | +0.8% | -3.4% | +10.4% | -5.5% | +6.7% | -1.6% | +2.4% | -5.4% |
| YoY Change | — | — | — | — | -4.9% | +8.8% | -3.4% | -0.8% | +1.7% | -3.3% | +1.8% | +7.6% | +1.7% | +7.6% | +9.6% | +1.6% | +1.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.